Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis (2019) Ooi BNS, Loh H, Ho PJ, Milne RL, Giles G, Gao C, Kraft P, et al. Journal article Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study (2019) Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C, et al. Journal article Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study (2019) Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus , Foerster F, Grischke EM, et al. Journal article Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk (2019) Vachon CM, Scott CG, Tamimi RM, Thompson DJ, Fasching P, Stone J, Southey MC, et al. Journal article Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto (2019) Laakmann E, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, et al. Journal article Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019) Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al. Conference contribution Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial (2019) Fasching P, Quek RGW, Bhattacharyya H, Hurvitz SA, Rugo HS, Ettl J Conference contribution Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy (2019) Huang M, Qi CZ, Ramsey S, Briggs A, Zhao J, Haiderali A, Karantza V, et al. Conference contribution A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) (2019) Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, et al. Journal article Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomaki K, Andrulis IL, Anton-Culver H, Arason A, et al. Journal article